Data / Form D filings / Inversion Therapeutics, Inc.
Inversion Therapeutics, Inc.: Form D filing
Inversion Therapeutics, Inc., a biotechnology company in Burlingame, CA, filed a Form D with the SEC in 2025. The latest, on August 27, 2025, reports $6.9 million sold of a $11.1 million offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1341 COLUMBUS AVENUE, Burlingame, CA, 94010
- Phone
- (650) 430-5176
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2024
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2077706
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 27, 2025 | New notice | $11,110,779 | $6,910,684 | $4,200,095 | 4 | Jun 20, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Samad Michael Wahid, M.D. | Director | |
| James A. Wells, Ph.D. | Executive Officer, Director | |
| Jeremy A. Caldwell, Ph.D. | Director | |
| William Michael Kavanaugh, M.D. | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Aug 25, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Inversion Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.